Flashcards · Module 21
🫀 Acute Heart Emergencies (Geriatric Cardiology)
4 of 4 cards published · read by the site’s author on 17 November 2026
TAVI in Frail Octogenarians: Fixing severe aortic stenosis without cracking the chest
Needs clinical review
The Clinical Revolution:
In the past, an 84-year-old with severe symptomatic calcific aortic stenosis (fainting, chest pain, breathlessness) whose open-heart surgery (SAVR) risk was prohibitive had no valve option; TAVI was first used for exactly these patients. Today, Transcatheter Aortic Valve Implantation (TAVI) replaces the valve via a catheter through the femoral artery!
Why TAVI is a Game-Changer in Geriatrics:
No Sternotomy: No cracking open the chest bone.
No Heart-Lung Bypass Machine: TAVI avoids cardiopulmonary bypass, long blamed for cognitive decline after heart surgery, though cognitive change after TAVR and surgical valve replacement looks broadly similar.
Rapid Discharge: on a standard pathway, selected transfemoral patients walk 4–6 hours after the procedure, and about 80% go home the next day.
Unique Complications to Watch For:
⚡ Heart Block (AV Block / LBBB): the implanted valve can compress the conduction tissue near the membranous septum, so permanent pacemakers are common after TAVI.
🌊 Paravalvular Leak: Calcified native leaflets can prevent a perfect seal, leaving mild-to-moderate aortic regurgitation.
🩸 Vascular Damage: Dissection or hematoma in fragile, tortuous femoral/iliac arteries.
When is TAVI NOT Appropriate?
If the patient is bedbound with end-stage dementia or metastatic cancer (life expectancy <1 year), TAVI will not restore meaningful functional quality of life.
Sources checked (7) · 15 November 2026
- Transcatheter aortic valve implantation: latest evidence, gaps in knowledge, and future directions (2025)
- Mechanical complications of transcatheter aortic valve replacement: a review article (2026)
- Cognitive and functional status after transcatheter and mini-aortic valve replacement: a prospective cohort study (2026)
- Enhanced recovery after surgery turnkey order set for periprocedural care of the patient undergoing transcatheter aortic valve replacement (2026)
- Beyond Technical Success: The Lifetime Consequences of Prosthesis-Patient Mismatch, Paravalvular Leak, and Permanent Pacemaker Implantation After Transcatheter Aortic Valve Replacement (2026)
- Introducing palliative care into the management of patients disqualified from transcatheter aortic valve implantation (2026)
- Transcatheter Aortic Valve Implantation in Cancer Patients: A Contemporary Review of the Specific Challenges, the Outcomes, Risk Stratification, and Decision-Making (2026)
Note: In the Optimize PRO study the 30-day pacemaker rate was 11.1% overall and 6.4% with the cusp-overlap technique. (Transcatheter aortic valve implantation: latest evidence, gaps in knowledge, and future directions (2025))
Sick Sinus Syndrome (Tachy-Brady Syndrome): Too fast, then too slow
Needs clinical review
The Anatomical Problem:
Fibrous tissue builds up in the SA node with age (collagen is about 24% of the infant node and about 70% of the adult node), and loss of pacemaker cells with fibrous replacement is common in sinus node dysfunction.
What is Tachy-Brady Syndrome?
The sick sinus node swings between two extremes:
🏎️ Tachycardia Phase: paroxysms of atrial fibrillation or flutter (tachycardia complicates about half of sick sinus syndrome).
🛑 Bradycardia / Pause Phase: sinus arrest or pauses of 3 seconds or more → causing syncope and falls.
Treating the Fast Phase:
Slowing the fast AF (rate control) matters too: patients with the tachy-brady form who have a pacemaker may benefit from a lower heart-rate goal.
The Trap: when the AF stops, long pauses lasting several seconds may follow, and a pause can set off the next run of AF.
The Fix:
🥇 Pacemaker: implantation is the mainstay of treatment for sick sinus syndrome.
Sources checked (4) · 15 November 2026
- Tachycardia-bradycardia syndrome: Electrophysiological mechanisms and future therapeutic approaches (Review). (2017)
- Fibrosis: a structural modulator of sinoatrial node physiology and dysfunction (2015)
- Comparing the Feasibility of S-Patch vs 24-Hour Holter in Frail Older People With Falls: Randomized Open-Label Crossover Pilot Study (2026)
- 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. (2024)
Hypertensive Urgency vs. Emergency: Why lowering high blood pressure too fast can cause a stroke
Needs clinical review
The Scenario:
An asymptomatic 82-year-old in the clinic has a routine BP of 205/105 mmHg. The intern wants to give IV Labetalol or sublingual Nifedipine to "get the number down immediately." STOP! That could cause a stroke!
Urgency vs. Emergency:
| Condition | Target-Organ Damage Present? | Symptoms | Setting & Speed of Reduction |
|---|---|---|---|
| Hypertensive EMERGENCY | ✅ YES (acute aortic dissection, flash pulmonary edema, acute MI, hypertensive encephalopathy) | Severe chest pain, dyspnea, papilledema, acute confusion | ICU admission: IV titratable infusions (Nicardipine, Labetalol); initial SBP reduction of about 25% in the 1st hour |
| Hypertensive URGENCY | ❌ NO target-organ damage | Mild headache or completely asymptomatic | Outpatient / Ward: Oral medications; lower BP gradually over 24 to 48 hours! |
The Cerebral Autoregulation Shift:
Years of hypertension and arterial stiffness shift the brain's autoregulation curve to the right. The brain requires higher systemic pressures to keep blood flowing through microvessels. If you crash their BP from 205 down to 130 in 30 minutes:
Brain: watershed infarcts have been reported after urgent lowering of blood pressure.
Other organs suffer from low perfusion too, such as the spinal cord's mid-thoracic 'watershed' zone.
Kidney: low renal perfusion has traditionally been linked to acute tubular necrosis.
Sources checked (6) · 15 November 2026
- Hypertensive crisis in the critically ill (2026)
- Current guidelines in hypertension management with special focus on management of extremely high blood pressure: a systematic review (2025)
- Executive Summary of the 2024 Philippine Clinical Practice Guidelines on the Diagnosis and Management of Acute Severe Blood Pressure Elevation (2026)
- Association between continuous low-dose norepinephrine infusion and intraoperative hypotension burden in patients aged 80 years and older undergoing total hip arthroplasty: a retrospective cohort study (2026)
- Spinal cord ischemia in patients on venoarterial extracorporeal membrane oxygenation: a literature review (2026)
- Translating the pathophysiology of sepsis-associated acute kidney injury: From bench to bedside (2026)
Cardio-Oncology: Anthracyclines vs. Trastuzumab (Type I vs Type II heart damage)
Needs clinical review
Heart Disease Induced by Cancer Therapies:
With more older adults surviving cancer, recognizing cardiotoxicity is crucial:
| Feature | Type I Cardiotoxicity (Anthracyclines) 💀 | Type II Cardiotoxicity (HER2 Inhibitors) 🔄 |
|---|---|---|
| Prototype Drug | Doxorubicin (Adriamycin) | Trastuzumab (Herceptin) |
| Mechanism | Generates reactive oxygen species, topoisomerase IIβ inhibition → irreversible myocyte necrosis & fibrosis | Disrupts HER2 survival signaling in cardiomyocytes → cell stunning / functional shutdown |
| Dose-Dependent? | ✅ YES (risk rises sharply beyond a cumulative 450–550 mg/m²) | ❌ NO (occurs independently of dosage) |
| Reversibility | ❌ Irreversible, leading to chronic HFrEF | ✅ Usually reversible (no structural damage to the heart muscle cells) |
| Monitoring | Baseline echo with GLS; every 3 months if high risk (e.g. cumulative dose ≥250 mg/m²) | Every 3 months when combined with an anthracycline; otherwise by risk |
VEGF Inhibitors (Bevacizumab, Sunitinib):
Cause microvascular rarefaction, presenting with hypertension and proteinuria.
Sources checked (4) · 15 November 2026
- Cardiotoxicity of Antitumor Agents: Therapeutic Challenges in Heart Failure with Reduced and Preserved Ejection Fraction (2026)
- Doxorubicin-Induced Cardiotoxicity: A Comprehensive Update (2025)
- Chemotherapy-Induced Cardiotoxicity: Mechanisms, Detection and Emerging Therapies in Cardio-Oncology (2025)
- Onco-hypertension: hypertension induced by VEGF pathway inhibition (2026)
Note: Trastuzumab cardiotoxicity occurs independently of dosage. (Chemotherapy-Induced Cardiotoxicity: Mechanisms, Detection and Emerging Therapies in Cardio-Oncology (2025))